Rock Out like It’s the 00s
    Listen Now

    Listen to Stations For You

    Change genre preferences

    .
    .
    . .
    .

    Chris Toombs, Proniras co-founder and chief scientific officer. (Accelerator Life Science Partners Photo)

    Accelerator Life Science Partners, a Seattle-based life sciences investment fund and umbrella company, unveiled its newest company with a bang Friday.

    Proniras Corporation was created to develop the seizure drug tezampanel, originally created by Eli Lilly, and it will do so with the support of an .5 million contract from the U.S. Department of Health and Human Service’s Biomedical Advanced Research and Development Authority (BARDA).

    .

    Breaking News Emails

    .
    SPECIAL PROJECTS .

    Featured Newsrooms

    .

    TRILOBITES

    Fungi Physics: How Those Spores Launch Just Right

    .

    As a seizure treatment, tezampanel would be unique among current offerings. The drug works by blocking certain receptors in the central nervous system, preventing excessive neurological activity. Most seizure medications today are benzodiazepines, which are thought to work in the opposite way: By reducing the activity of neurotransmitters in the brain.

    Proniras currently has three full-time employees and is based in Accelerator’s Seattle headquarters. It is the seventeenth startup to join Accelerator’s portfolio.

    .